Physician profile
Elias Hanna Bassil
NPI 1679035695
$80,167.60
in general payments reported to CMS, 2019-2025
7 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $43.22 · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Travel and Lodging: $8,403 · Food and Beverage: $1,890 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,690.00 |
| Travel and Lodging | $8,403.44 |
| Food and Beverage | $1,890.26 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $79,865.73 | 2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $63.99 | 2025 | Soliris |
| Novartis Pharmaceuticals Corporation | $30.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.93 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $23.44 | 2024 | Keveyis |
| Merck Sharp & Dohme LLC | $19.78 | 2024 | Prevymis |
| Amgen INC. | $17.86 | 2025 | Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Bassil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.